WANBURYNSEWANBURY LIMITED· Pharmaceuticals & BiotechnologyHighNeutral
Announced Wed, 22 Jul, 2026 · 15:10 IST

USFDA inspection at Tanuku facility ends with 6 observations in Form 483

WANBURY · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-3.2%Reaction day
₹341.00
prior close
₹327.80
announcement price
In-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used-1.2%-2.0% vs market
Pharmaceuticals peers, median of 165sector-1.6%-1.6% vs sector

On the reaction day the stock moved 2.0 pts less than Nifty Microcap 250 and 1.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+0.4
10m
+0.1
15m
+0.7
30m
—
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-3.2-1.2-2.0-1.6-1.6
Next day
-3.5-1.9-1.7-2.4-1.1
2d
-2.6-1.4-1.2-2.4-0.2
3d
-3.7-0.1-3.6-1.3-2.4
4d
-8.5-1.4-7.1-2.4-6.1
5d
-10.6-1.0-9.7-1.7-8.9
1w
-14.2-0.4-13.8-1.9-12.3
15d
-23.1+3.2-26.2-0.3-22.8
1m
-22.9+4.4-27.3-1.1-21.8
2m
-34.7+4.6-39.2+1.1-35.7
3m
-45.7-3.6-42.1-6.4-39.2
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

USFDA completed a routine cGMP inspection at Wanbury's Tanuku facility in Andhra Pradesh from July 13 to July 17, 2026. The inspection ended with a Form 483 containing six observations. The company will respond within the stipulated time and says all observations are addressable. Wanbury expects no impact on manufacturing, US exports, or financial performance.

Likely market impact

Form 483 observations are typically addressable; company expects no material impact on operations or finances, though USFDA follow-up remains a watch point.